Overview

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Status:
Completed
Trial end date:
2017-06-02
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries, Ltd.
Treatments:
(T,G)-A-L
Glatiramer Acetate